JS203 With Chemotherapy Compared to Rituximab With Chemotherapy for Returning Diffuse Large B-Cell Lymphoma
Compares JS203 plus chemotherapy with rituximab plus chemotherapy in adults with relapsed or treatment-resistant lymphoma.
Plain-language title generated from the registry record
Registry title: A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07808827, who can take part
Where in China
- Beijing Cancer HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Junshi Bioscience Co., Ltd.
- Trial code
- NCT07808827
- Record updated
- 14 October 2026
- Original description
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.Read full original descriptionShow less
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Inclusion: Patients must meet all of the following inclusion criteria to be enrolled:; Age range: 18 to 75 years old (inclusive), both male and female are acceptable; ECOG: 0-1；; One of the confirmed histologies below with CD20-positivity:; DLBCL, not otherwise specified (NOS), including de novo or histologically transformed from follicular lymphoma (FL)/Marginal Zone Lymphoma(MZL) "Double-hit" or "triple-hit" DLBCL , including de novo or histologically transformed from FL/MZL FL Grade 3B T-cell/histiocyte-rich large B-cell lymphoma; At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment；; Acceptable organ function at screening；.
Exclusion: Previously received CD20-CD3 bispecific antibody treatment；; Previous allogeneic hematopoietic stem cell transplantation；; Previous solid organ transplantation; A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；; History of autoimmune diseases; Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH); Patients with a history of progressive multifocal leukoencephalopathy (PML); A known or suspected history of CNS lymphoma (including primary or secondary); There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage).